Combined activation of PPAR-gamma and RXR [retinoid X receptor] pathways by rosiglitazone (Avandia) and bexarotene (Targretin) in hematological malignancies
Phase of Trial: Phase I
Latest Information Update: 05 Jun 2015
At a glance
- Drugs Bexarotene (Primary) ; Rosiglitazone (Primary)
- Indications Haematological malignancies
- Focus Biomarker; Therapeutic Use
- 30 Nov 2005 New trial record.